SST and neoplasm: Approved [68 Ga]-SST radiopharmaceuticals are routinely used for diagnostic PET/CT imaging to assess SST-expressing tumor burden and to assess eligibility for targeted therapy with the approved SST-targeted [177Lu]Lu-DOTATATE.